Adverse effects of treatment · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
Oral plus nebulised antibiotics showed no clear difference in adverse effects of treatment compared with oral antibiotics plus nebulised placebo (low certainty).
1 finding from 1 review
Time until next positive MRSA isolate (from clinically relevant respiratory culture) · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life: CFRSD‐CRISS symptom score · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
Change in weight (kg) · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
Exacerbation frequency · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
Adverse effects of treatment · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
Eradication of MRSA · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
Oral plus nebulised antibiotics showed no clear difference in eradication of MRSA compared with oral antibiotics plus nebulised placebo (low certainty).
1 finding from 1 review
Time until next positive MRSA isolate (from clinically relevant respiratory culture) · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported outcome measures (PROMs) · adults with fractures of the distal femur
1 finding from 1 review
PROMs (long term) Measurements: SMFA (range 0–100, higher values indicate worse function) KSS (range 0–100, where higher values indicate better function) · adults with fractures of the distal femur
1 finding from 1 review
QoL · adults with fractures of the distal femur
2 findings from 1 review
Pain · adults with fractures of the distal femur
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants experiencing an attacka · people with familial Mediterranean fever
Colchicine (oral) may leads to lower number of participants experiencing an attacka,b compared with placebo (low certainty).
1 finding from 1 review
Prevention of AA amyloidosis · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse drug reactions · people with familial Mediterranean fever
1 finding from 1 review
Acute‐phase response · people with familial Mediterranean fever
1 finding from 1 review
Number of participants experiencing an attacka · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of attacks · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time between attacks · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found